Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $760.97 million
- Book Value:
- Revenue TTM:
- $96.97 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Regenxbio Inc had its IPO on 2015-09-17 under the ticker symbol RGNX.
The company operates in the Healthcare sector and Biotechnology industry. Regenxbio Inc has a staff strength of 401 employees.
Shares of Regenxbio Inc opened at $17.24 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $17.1 - $17.51, and closed at $17.32.
This is a +0.06% increase from the previous day's closing price.
A total volume of 330,366 shares were traded at the close of the day’s session.
In the last one week, shares of Regenxbio Inc have slipped by -4.47%.
Regenxbio Inc's Key Ratios
Regenxbio Inc has a market cap of $760.97 million, indicating a price to book ratio of 1.8252 and a price to sales ratio of 2.0631.
In the last 12-months Regenxbio Inc’s revenue was $96.97 million with a gross profit of $-184274000 and an EBITDA of $-250092992. The EBITDA ratio measures Regenxbio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Regenxbio Inc’s operating margin was -274.7% while its return on assets stood at -20.35% with a return of equity of -52.91%.
In Q2, Regenxbio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 38.8%.
Regenxbio Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-6.16 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.26. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Regenxbio Inc’s profitability.
Regenxbio Inc stock is trading at a EV to sales ratio of 1.531 and a EV to EBITDA ratio of 5.9351. Its price to sales ratio in the trailing 12-months stood at 2.0631.
Regenxbio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $682.46 million
- Total Liabilities
- $117.89 million
- Operating Cash Flow
- Capital Expenditure
- $2.58 million
- Dividend Payout Ratio
Regenxbio Inc ended 2023 with $682.46 million in total assets and $0 in total liabilities. Its intangible assets were valued at $682.46 million while shareholder equity stood at $405.86 million.
Regenxbio Inc ended 2023 with $0 in deferred long-term liabilities, $117.89 million in other current liabilities, 4000.00 in common stock, $-580290000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $68.60 million and cash and short-term investments were $320.08 million. The company’s total short-term debt was $6,326,000 while long-term debt stood at $0.
Regenxbio Inc’s total current assets stands at $378.81 million while long-term investments were $95.30 million and short-term investments were $251.48 million. Its net receivables were $24.98 million compared to accounts payable of $11.64 million and inventory worth $15.11 million.
In 2023, Regenxbio Inc's operating cash flow was $0 while its capital expenditure stood at $2.58 million.
Comparatively, Regenxbio Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Regenxbio Inc stock is currently trading at $17.32 per share. It touched a 52-week high of $27.2 and a 52-week low of $27.2. Analysts tracking the stock have a 12-month average target price of $41.36.
Its 50-day moving average was $18.28 and 200-day moving average was $20.37 The short ratio stood at 14.43 indicating a short percent outstanding of 0%.
Around 790.8% of the company’s stock are held by insiders while 9297.5% are held by institutions.
Frequently Asked Questions About Regenxbio Inc
Similar Industry Stocks (Biotechnology)
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. In addition, it also develops RGX-121 for the treatment of mucopolysaccharidosis type II and is in Phase III clinical trial; RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. Further, the company also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.